Literature DB >> 9256196

Prolonged survival of mouse skin allografts in recipients treated with donor splenocytes and antibody to CD40 ligand.

T G Markees1, N E Phillips, R J Noelle, L D Shultz, J P Mordes, D L Greiner, A A Rossini.   

Abstract

Combined treatment with antibody against CD40 ligand and one transfusion of donor splenocytes prolonged survival of fully mismatched BALB/c skin allografts on C57BL/6 recipients, with approximately 20% of grafts surviving > 100 days. In vitro alloresponsiveness in treated animals was reduced in the immediate post-transplantation period, but by day 100 was increased despite the presence of a successful allograft. The presence of alloreactivity on day 100 was confirmed in vivo by adoptive transfer, which suggests that our protocol had induced either a state of "split tolerance" or "graft accommodation." Mice with skin grafts that had survived for > or = 100 days revealed no evidence of lymphoid chimerism. Treatment with donor splenocytes and antibody against CD40 ligand permits long-term survival of highly antigenic donor skin allografts despite the presence of functionally intact alloreactive lymphocytes.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9256196     DOI: 10.1097/00007890-199707270-00026

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  39 in total

1.  Long-term survival and function of intrahepatic islet allografts in rhesus monkeys treated with humanized anti-CD154.

Authors:  N S Kenyon; M Chatzipetrou; M Masetti; A Ranuncoli; M Oliveira; J L Wagner; A D Kirk; D M Harlan; L C Burkly; C Ricordi
Journal:  Proc Natl Acad Sci U S A       Date:  1999-07-06       Impact factor: 11.205

2.  Skin allograft maintenance in a new synchimeric model system of tolerance.

Authors:  N N Iwakoshi; T G Markees; N Turgeon; T Thornley; A Cuthbert; J Leif; N E Phillips; J P Mordes; D L Greiner; A A Rossini
Journal:  J Immunol       Date:  2001-12-01       Impact factor: 5.422

Review 3.  T-cell activation and transplantation tolerance.

Authors:  Bhavana Priyadharshini; Dale L Greiner; Michael A Brehm
Journal:  Transplant Rev (Orlando)       Date:  2011-11-08       Impact factor: 3.943

4.  Alloantibodies prevent the induction of transplantation tolerance by enhancing alloreactive T cell priming.

Authors:  Audrea M Burns; Anita S Chong
Journal:  J Immunol       Date:  2010-12-06       Impact factor: 5.422

5.  Study of relieving graft-versus-host disease by blocking CD137-CD137 ligand costimulatory pathway in vitro.

Authors:  Kailin Xu; Chaohong Li; Xiuying Pan; Bing Du
Journal:  Int J Hematol       Date:  2007-07       Impact factor: 2.490

6.  TLR agonists abrogate costimulation blockade-induced prolongation of skin allografts.

Authors:  Thomas B Thornley; Michael A Brehm; Thomas G Markees; Leonard D Shultz; John P Mordes; Raymond M Welsh; Aldo A Rossini; Dale L Greiner
Journal:  J Immunol       Date:  2006-02-01       Impact factor: 5.422

7.  Rapid quantification of naive alloreactive T cells by TNF-alpha production and correlation with allograft rejection in mice.

Authors:  Michael A Brehm; Julie Mangada; Thomas G Markees; Todd Pearson; Keith A Daniels; Thomas B Thornley; Raymond M Welsh; Aldo A Rossini; Dale L Greiner
Journal:  Blood       Date:  2006-09-14       Impact factor: 22.113

8.  Costimulatory blockade of CD154-CD40 in combination with T-cell lymphodepletion results in prevention of allogeneic sensitization.

Authors:  Hong Xu; Jun Yan; Yiming Huang; Paula M Chilton; Chuanlin Ding; Carrie L Schanie; Li Wang; Suzanne T Ildstad
Journal:  Blood       Date:  2007-09-07       Impact factor: 22.113

Review 9.  Function of tumor necrosis factor receptor family members on regulatory T-cells.

Authors:  Robert H Arch
Journal:  Immunol Res       Date:  2005       Impact factor: 2.829

10.  Immunization with host-type CD8{alpha}+ dendritic cells reduces experimental acute GVHD in an IL-10-dependent manner.

Authors:  Tomomi Toubai; Chelsea Malter; Isao Tawara; Chen Liu; Evelyn Nieves; Kathleen P Lowler; Yaping Sun; Pavan Reddy
Journal:  Blood       Date:  2009-11-18       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.